ALBT - Avalon GloboCare Corp.
3.91
-0.050 -1.279%
Share volume: 6,508
Last Updated: 04-08-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.07%
PREVIOUS CLOSE
CHG
CHG%
$3.96
-0.05
-0.01%
Fundamental analysis
19%
Profitability
0%
Dept financing
25%
Liquidity
6%
Performance
40%
Company vs Stock growth
vs
327.887 K
345.159 K
17.272 K
5.27%
0.315
3.160
2.845
902.54%
Performance
5 Days
0.26%
1 Month
-28.78%
3 Months
13.33%
6 Months
1,746.95%
1 Year
965.10%
2 Year
119.66%
Key data
Stock price
$3.91
DAY RANGE
$3.90 - $4.10
52 WEEK RANGE
$0.16 - $11.66
52 WEEK CHANGE
$1,121.49
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-14-2025
Company detail
CEO: David K. Jin
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: http://www.avalon-globocare.com/
Employees: 5
IPO year: 2018
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Avalon GloboCare Corp. owns and operates commercial real estate properties in the United States and the People's Republic of China. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia. It is also developing RNA-based FASH-CARTM cell therapy platform.
Recent news
